Additionally, studies have evaluated the potentiation of treatment efficacy and duration after consecutive administration of a GnRH agonist and dienogest (2 mg/d) in women with recurrent endometriosis,37 and with combined uterine pathology.38 This evidence concerns the gene GNRH1 and endometriosis.